Cytek Biosciences, Inc. (CTKB)
| Market Cap | 666.73M |
| Revenue (ttm) | 197.71M |
| Net Income (ttm) | -17.56M |
| Shares Out | 131.51M |
| EPS (ttm) | -0.14 |
| PE Ratio | n/a |
| Forward PE | 24.34 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 615,776 |
| Open | 5.00 |
| Previous Close | 5.06 |
| Day's Range | 5.00 - 5.21 |
| 52-Week Range | 3.80 - 9.87 |
| Beta | 1.31 |
| Analysts | Buy |
| Price Target | 8.50 (+67.65%) |
| Earnings Date | Nov 5, 2024 |
About CTKB
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS ... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for CTKB stock is "Buy." The 12-month stock price forecast is $8.5, which is an increase of 67.65% from the latest price.
News
Cytek® Biosciences Brings Full Spectrum Profiling™ (FSP™) Technology to the Forefront at Major Clinical Conferences in the U.S. and Europe
FREMONT, Calif., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB) is set to elevate its presence at this year's premier clinical industry events across the globe.
Cytek Announces Resignation of Chief Operating Officer Chris Williams
FREMONT, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced that its Chief Operating Officer, Chris Williams,...
Cytek® Biosciences Achieves ISO 13485 Certification at San Diego Reagent Manufacturing Facility
FREMONT, Calif., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Today Cytek Biosciences, Inc. (Nasdaq: CTKB) announced that its San Diego reagent manufacturing facility has been awarded EN ISO 13485:2016 Quality M...
Cytek Biosciences, Inc. (CTKB) Q2 2024 Earnings Call Transcript
Cytek Biosciences, Inc. (NASDAQ:CTKB) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Paul Goodson - Investor Relations Wenbin Jiang - Chief Executive Officer William ...
Cytek® Biosciences Automates Panel Design with New Intelligent Algorithm
Cytek has developed a revolutionary tool to automate panel design. SpectroPanel is an intelligent algorithm that suggests optimized panels in minutes.
Cytek Biosciences to participate at the Goldman Sachs 45th Annual Global Healthcare Conference
FREMONT, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the upcoming G...
1-Laser and 2-Laser 6-Color TBNK Reagents from Cytek® Biosciences Approved for Clinical Use in China
FREMONT, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- Today Cytek Biosciences, Inc. (Nasdaq: CTKB) announced that its 1-laser and 2-laser 6-color TBNK reagent cocktails have received China National Medica...
Lab Instrument Industry Update - New Commercial Entrants
Lab Instrument and Services providers in the healthcare industry can generate high recurring revenues. Many loss-making instrument makers in the industry may not provide meaningful returns and carry h...
Cytek® Biosciences Adds Ability to Detect Subcellular Particles to Its Industry-Leading Cell Analysis Systems
FREMONT, Calif., May 20, 2024 (GLOBE NEWSWIRE) -- Today Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, officially announced its Enhanced Small Particle (ESP™) Detec...
Cytek Biosciences, Inc. (CTKB) Q1 2024 Earnings Call Transcript
Cytek Biosciences, Inc. (NASDAQ:CTKB) Q1 2024 Earnings Conference Call May 8, 2024 4:30 PM ET Company Participants Paul Goodson - Investor Relations Wenbin Jiang - Chief Executive Officer William McC...
Cytek Biosciences Reports First Quarter 2024 Financial Results
FREMONT, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results ...
Cytek® Biosciences to Spotlight Cell Analysis Solutions at Upcoming Conferences in the United States and Europe
FREMONT, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, continues its commitment to advancing the cell analysis market by...
Cytek Biosciences to Report First Quarter 2024 Financial Results on May 8, 2024
FREMONT, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced it will report financial results for the first qu...
Cytek Biosciences: Undisputed Next-Gen Flow Cytometry Leader
Cytek Biosciences is a leading cellular analysis instrument maker with a focus on the Aurora flow cytometry platform. Despite a downturn in the healthcare market, Cytek has maintained revenue growth a...
Cytek® Biosciences Names William McCombe Chief Financial Officer
Experienced executive with extensive background as CFO for global corporations across dynamic sectors Cytek reaffirms 2024 outlook FREMONT, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences...
Cytek® Biosciences Opens New Facility to Address Increasing Global Demand for Cutting-Edge Cell Analysis Solutions
Cytek Biosciences has opened a 50,000-square-foot facility in Wuxi, China to meet the growing worldwide demand for comprehensive cell analysis solutions
Cytek Biosciences, Inc. (CTKB) Q4 2023 Earnings Call Transcript
Cytek Biosciences, Inc. (CTKB) Q4 2023 Earnings Call Transcript
Cytek Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Outlook
FREMONT, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results...
Cytek Biosciences to Participate in Upcoming Investor Conferences
FREMONT, Calif., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the following...
Cytek Biosciences to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024
FREMONT, Calif., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced it will report financial results for the fourth qu...
Cytek® Biosciences Signs Agreement with CRG and UPF to Accelerate Scientific Discoveries
Cytek Biosciences has signed an agreement with The Centre for Genomic Regulation and the Pompeu Fabra University to accelerate scientific discoveries.
Cytek Biosciences Announces Preliminary Full Year 2023 Revenue Results
FREMONT, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced preliminary, unaudited revenue results for the ful...
Cytek Biosciences to present at the 42nd Annual J.P. Morgan Healthcare Conference
FREMONT, Calif., Dec. 28, 2023 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the upcoming ...
Cytek® Biosciences Introduces the Cytek Orion™ Reagent Cocktail Preparation System, the First-of-its-Kind Automated Cocktail Preparation Instrument for Flow Cytometry
The new Cytek Orion reagent cocktail preparation system simplifies & accelerates laboratory workflow, assures consistent experimental results & saves time.
Why these stocks could lose money even if the market gains
According to a study published this summer in The Review of Financial Studies, these vulnerable stocks are the ones that are most difficult to borrow and then sell short.